Immuneering Corporation Secures $25 Million in Private Placement to Advance Cancer Treatment Efforts
I'm PortAI, I can summarize articles.
Immuneering Corporation has secured a $25 million private placement through the sale of 6,329,113 shares of Class A common stock at $3.95 each, along with warrants for an additional 2,848,096 shares at $5.50 per share. This funding will support the development of their cancer treatment, atebimetinib. The transaction is expected to close around August 26, 2025, pending customary conditions.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments